Source: ERS Skills course: Multi-disciplinary care in thoracic oncology
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Kostas Syrigos (Athens, Greece). Clinical impact of immunotherapy in NSCLC treatment landscape. ERS Skills course: Multi-disciplinary care in thoracic oncology

Member's Comments

No comment yet.

Related content which might interest you: Impact of COPD on prognosis of lung cancer: the prespective of immunotherapy treatment Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021 Bevacizumab shows survival benefit for non-small lung cancer patients who received subsequent pemetrexed treatment but not had a therapeutic effect in clinical practice Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Impact of antibiotics on immunotherapy response in lung cancer patients Source: International Congress 2019 – Treatment of lung cancer Year: 2019 The correlation between clinical and pathomorphological impacts of induction chemotherapy and long-term results of multimodality treatment for IIIA stage non-small cell lung cancer Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Radiation therapy for augmenting the efficacy of immunotherapy in advanced non-small cell lung cancer: a case-controlled study Source: ERJ Open Res, 6 (1) 00189-2019; 10.1183/23120541.00189-2019 Year: 2020 Efficacy and prognostic factors of first-line afatinib treatment for the EGFR-mutated non-small cell lung cancer in the real world Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020 Clinical outcome of S-1 monotherapy in patients with advanced non-small cell lung cancer after treatment of pemetrexed Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Safety and tolerability of gefitinib in advanced NSCLC: overview of clinical experience Source: Eur Respir J 2003; 22: Suppl. 45, 32s Year: 2003 Influence of the limited lung function to the outcome of the surgical treatment in patients with NSCLC Source: Annual Congress 2003 - Lung function testing for preoperative evaluation in lung cancer patients Year: 2003 Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer Source: Eur Respir J 2013; 42: 1119-1133 Year: 2013 Immunopathology of advanced forms of NSCLC: the influence of induction chemotherapy Source: Eur Respir J 2003; 22: Suppl. 45, 362s Year: 2003 A microsimulation model to assess the economic impact of immunotherapy in non-small cell lung cancer Source: ERJ Open Res, 6 (2) 00174-2019; 10.1183/23120541.00174-2019 Year: 2020 Treatment landscape in oncogene driven advanced NSCLC Source: ERS Skills course: Multi-disciplinary care in thoracic oncology Year: 2019 Therapeutic strategy for ALK/ROS driven NSCLC Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019 Impact of radiotherapy on outcomes of nivolumab in advanced non-small cell lung cancer: a case controlled study Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018 Biomarkers for non-small cell lung cancer (NSCLC) treatment: examples and unmet needs, a clinical perspective Source: International Congress 2014 – From bench to bedside: biomarkers and biobanking for lung cancer in 2014 Year: 2014 Systematic evaluation of the efficacy–effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer Source: Eur Respir J, 52 (6) 1801100; 10.1183/13993003.01100-2018 Year: 2018 NSCLC management Source: ERS Skills Course 2017 - Summer school of adult respiratory medicine Year: 2017